Skip to main content
GENETIC TECHNOLOGIES LIMITED logo

GENETIC TECHNOLOGIES LIMITED — Investor Relations & Filings

Ticker · GTG ISIN · AU000000GTG7 LEI · 529900YYKY7FRC90M744 ASX Human health and social work activities
Open in API
Filings indexed 1,303 across all filing types
Latest filing 2003-04-23 Director's Dealing
Country AU Australia
Listing ASX GTG

About GENETIC TECHNOLOGIES LIMITED

https://gtglabs.com/

Genetic Technologies Limited is a molecular diagnostics company focused on the development and commercialization of predictive genetic risk assessment tools. The company specializes in the geneType platform, which integrates clinical risk factors with polygenic risk scores to provide comprehensive risk assessments for various chronic diseases. Its portfolio includes tests for breast cancer, colorectal cancer, prostate cancer, melanoma, type 2 diabetes, and coronary artery disease. By identifying individuals at high risk of developing these conditions, the company enables healthcare providers to implement personalized screening and preventative health strategies. Genetic Technologies Limited serves clinicians and patients globally, aiming to improve health outcomes through early detection and precision medicine.

Recent filings

Filing Released Lang Actions
Initial Director's Interest Notice 2 pages ?Kb
Director's Dealing Classification · 100% confidence The document is titled 'Initial Director's Interest Notice' and references ASX listing rule 3.19A.1 and section 205G of the Corporations Act. It details the director's relevant interests in securities, including holdings and contracts, which is characteristic of insider or director share transactions. The document length is short (2526 characters) and contains no financial statements or company performance data. This matches the definition of Director's Dealing filings, which report personal share transactions by company directors and executives (insider trades).
2003-04-23 English
PGGP Research Project - Second Progress Report 2 pages ?Kb
Regulatory Filings Classification · 90% confidence The document is a progress report on a research project by Genetic Technologies Limited, detailing phases of the project, funding agreements, and future plans. It is addressed to the Australian Stock Exchange Company Announcements Office, indicating it is a formal update to shareholders and the market. The content focuses on research progress and funding updates rather than financial results, management changes, or regulatory filings. The document length is 3233 characters, which is relatively short and does not contain financial statements or detailed financial data. It is not an announcement of a report publication but a substantive update on a project. Given the nature of the content, it fits best under the category of Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories like Annual Report, Earnings Release, or Capital Update.
2003-04-21 English
Genetic Susceptibility Testing - A Second Progress Report 3 pages ?Kb
Regulatory Filings Classification · 90% confidence The document is a letter dated April 17, 2003, addressed to the Australian Stock Exchange Company Announcements Office. It provides a progress update on Genetic Technologies Limited's genetic susceptibility testing program, including strategic alliances, new board appointments, and operational plans. The content is a narrative progress report rather than a formal financial report, regulatory filing, or announcement of voting results. It does not contain financial statements, earnings data, or regulatory certifications. The document length is 4084 characters, which is relatively short and more consistent with an announcement or progress update rather than a full report. Given the nature of the content as a progress report on a specific project and the absence of financial or regulatory data, the most appropriate classification is Regulatory Filings (RNS), which serves as a fallback for miscellaneous announcements that do not fit other categories.
2003-04-16 English
Commitments Test Entity - Third Quarter Report 5 pages ?Kb
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Appendix 4C' and is described as a 'Quarterly report' for entities admitted on the basis of commitments. It contains detailed financial data including consolidated cash flow statements for the current quarter and year to date, payments to directors, financing facilities, and compliance statements. The presence of quarterly financial data and the explicit mention of the quarter ended date (31 March 2003) indicate this is a periodic financial report shorter than a full fiscal year. The document is about 15,000 characters long, which is substantial and contains actual financial data, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2003-04-08 English
Grants License to Assoc Regional & University Pathologists 1
Capital/Financing Update Classification · 90% confidence The document is a short announcement dated April 7, 2003, addressed to the Australian Stock Exchange. It announces that Genetic Technologies Limited has granted a license to Associated Regional & University Pathologists (ARUP) for its patents. The content is a corporate announcement about licensing activity, not a financial report, regulatory filing, or management change. The document length is only 1308 characters, indicating it is a brief announcement. There is no indication of financial results, board changes, or regulatory compliance details. Therefore, it fits best under Capital/Financing Update (CAP) as it relates to licensing revenue and intellectual property monetization, which is a form of capital activity.
2003-04-06 English
Licensing the Non-Coding Patents 2 pages ?Kb
Legal Proceedings Report Classification · 95% confidence The document is a progress report addressed to the Australian Stock Exchange (ASX) regarding licensing activities and legal actions related to the company's patents. It provides updates on licensing agreements, payments received, ongoing discussions with potential licensees, and initiation of litigation against patent infringers. The document is dated April 2003 and is titled as a 'Third Progress Report to the ASX'. It is not a full financial report, earnings release, or regulatory filing, but rather a detailed update on licensing and legal proceedings. Given the content focuses on legal proceedings and licensing enforcement actions, the most appropriate classification is a Legal Proceedings Report (LTR). The document length is under 5,000 characters, but it contains substantive information about legal actions, not just an announcement of a report publication, so it is not an RPA or RNS.
2003-04-01 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.